• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proteins . Computational Discovery of MERS-CoV Main Protease Inhibitors Through Screening and Molecular Dynamics Simulations

tetano

Editor, Senior Moderator
Proteins


. 2026 Mar 26.
doi: 10.1002/prot.70132. Online ahead of print.
Computational Discovery of MERS-CoV Main Protease Inhibitors Through Screening and Molecular Dynamics Simulations

Shahidul M Islam[SUP] 1 [/SUP], Md Saidur Rahman[SUP] 1 [/SUP], Sidhant Singla[SUP] 2 [/SUP], Robel Demissie[SUP] 3 [/SUP], Hyun Lee[SUP] 3 4 [/SUP]


Affiliations
Abstract

Targeting the main protease (Mpro) of coronaviruses has emerged as a promising therapeutic strategy for combating viral infections. Despite the global health threat posed by Middle East Respiratory Syndrome Coronavirus (MERS-CoV), no vaccines or antiviral drugs have been approved to date for its treatment. With a mortality rate approaching 35%, MERS-CoV remains a critical concern, particularly due to its potential for increased transmissibility through mutation. The viral main protease plays a pivotal role in the proteolytic processing of viral polyproteins, making it an attractive target for antiviral drug development. In this study, an in silico high-throughput screening was performed to identify potential inhibitors of MERS-CoV Mpro. A compound library comprising small molecules was curated from diverse sources, including DrugBank, CHEMBL, and known protease inhibitors from the Protein Data Bank. Top candidates were selected using molecular docking combined with a similarity-based search strategy, which prioritized compounds known to interact with Mpro and predicted to exhibit high binding affinity at its active site. The top-ranking candidates were further evaluated through molecular dynamics (MD) simulations to assess the conformational stability of the ligand-protein complexes. Binding free energies were subsequently calculated using multiple computational approaches, including the deep learning-based K[SUB]DEEP[/SUB] model, molecular mechanics/generalized born surface area (MM/GBSA), and free energy perturbation (FEP). Among the screened compounds, two molecules X2A and DB11779 (Danoprevir) consistently demonstrated superior binding affinities and stable interactions with MERS-CoV Mpro. These results agree well with experimental equilibrium dissociation constant (K[SUB]D[/SUB]) and half-maximal inhibitory concentrations (IC50). These findings highlight the capability of modern computational methods to generate accurate and robust binding data.

Keywords: IC50; MERS‐CoV; binding affinity (KD); free energy perturbation (FEP); molecular docking; molecular dynamics (MD); molecular mechanics/generalized born surface area (MM/GBSA).

 
Back
Top